Literature DB >> 1998990

A clinical study of nafazatrom in advanced human breast cancer.

A L Jones1, T J Powles, G V Forgeson, R C Coombes.   

Abstract

Prostaglandins (PGs) have been shown to inhibit tumour metastases in experimental animal systems. Nafazatrom is a pyrazolinone derivative that increases endogenous prostacyclin (PGI2) and has experimental anti-cancer activity. In the present study, nafazatrom was given to 47 women with advanced breast cancer; objective remission of metastases was seen in 2 patients and stabilisation of disease in 1 case. Nafazatrom was safe and well tolerated.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1998990     DOI： 10.1007/bf00685120

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  13 in total

1.  Antimetastatic effects associated with platelet reduction.

Authors:  G J Gasic; T B Gasic; C C Stewart
Journal:  Proc Natl Acad Sci U S A       Date:  1968-09       Impact factor: 11.205

2.  Phase I and pharmacologic evaluation of nafazatrom in patients with cancer.

Authors:  C D Haas; L H Baker; L J Evans
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

3.  Prostaglandin analogs as inhibitors of tumor cell DNA synthesis.

Authors:  K V Honn; M Romine; A Skoff
Journal:  Proc Soc Exp Biol Med       Date:  1981-04

4.  Dose dependent inhibition of B-16 melanoma growth in vivo by a synthetic analogue of PGE2.

Authors:  M G Santoro; G W Philpott; B M Jaffe
Journal:  Prostaglandins       Date:  1977-10

5.  Phase I clinical study of nafazatrom.

Authors:  G N Hortobagyi; N E Papadoupoulos; D Frye; J Ajani; J M Reuben
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

6.  Biotransformation and cardiovascular effects of arachidonic acid in the dog.

Authors:  K M Mullane; G J Dusting; J A Salmon; S Moncada; J R Vane
Journal:  Eur J Pharmacol       Date:  1979-03-01       Impact factor: 4.432

7.  Prostacyclin: a potent antimetastatic agent.

Authors:  K V Honn; B Cicone; A Skoff
Journal:  Science       Date:  1981-06-12       Impact factor: 47.728

8.  A clinical trial of nafazatrom (Bay g 6575) in advanced cancer.

Authors:  J F O'Donnell; S A Blakowski; L R Zacharski; D W Nierenberg; C T Coughlin; S Fein; E Philipp; G G Cornwell
Journal:  Am J Clin Oncol       Date:  1986-04       Impact factor: 2.339

9.  Assessment of response to therapy in advanced breast cancer.

Authors:  J L Hayward; P P Carbone; J C Heusen; S Kumaoka; A Segaloff; R D Rubens
Journal:  Br J Cancer       Date:  1977-03       Impact factor: 7.640

10.  Influence of prostaglandin analogues on epithelial cell proliferation and xenograft growth.

Authors:  P J Tutton; D H Barkla
Journal:  Br J Cancer       Date:  1980-01       Impact factor: 7.640
View more
  1 in total

Review 1.  Clinical significance of prostacyclin and thromboxane in cancer of the female breast and genital tract.

Authors:  S Nigam; A Zakrzewicz; S Eskafi; A Roscher
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.